DK0779810T3 - Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes - Google Patents

Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes

Info

Publication number
DK0779810T3
DK0779810T3 DK94927881T DK94927881T DK0779810T3 DK 0779810 T3 DK0779810 T3 DK 0779810T3 DK 94927881 T DK94927881 T DK 94927881T DK 94927881 T DK94927881 T DK 94927881T DK 0779810 T3 DK0779810 T3 DK 0779810T3
Authority
DK
Denmark
Prior art keywords
ketoconazole
diabetes
drugs
type
treatment
Prior art date
Application number
DK94927881T
Other languages
Danish (da)
English (en)
Inventor
Per Marin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Application granted granted Critical
Publication of DK0779810T3 publication Critical patent/DK0779810T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • B65B1/08—Methods of, or means for, filling the material into the containers or receptacles by vibratory feeders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK94927881T 1994-08-09 1994-08-09 Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes DK0779810T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1994/000729 WO1996004912A1 (en) 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Publications (1)

Publication Number Publication Date
DK0779810T3 true DK0779810T3 (da) 2003-10-20

Family

ID=20393155

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94927881T DK0779810T3 (da) 1994-08-09 1994-08-09 Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes

Country Status (14)

Country Link
US (2) US5849740A (de)
EP (2) EP1360960A1 (de)
JP (1) JP3825469B2 (de)
KR (1) KR100422162B1 (de)
AT (1) ATE244009T1 (de)
CA (1) CA2196174C (de)
CZ (1) CZ285290B6 (de)
DE (1) DE69432905T2 (de)
DK (1) DK0779810T3 (de)
ES (1) ES2202326T3 (de)
NO (1) NO314616B1 (de)
PT (1) PT779810E (de)
SI (1) SI0779810T1 (de)
WO (1) WO1996004912A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
SI0779810T1 (en) * 1994-08-09 2003-12-31 Cortendo Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
AU2002365122A1 (en) * 2001-08-23 2003-07-15 New England Biolabs, Inc. A method for engineering strand-specific, sequence-specific, dna-nicking enzymes
RS44304A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP2053409A1 (de) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Spezifische Marker für Stoffwechselsyndrome
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
EP1853266B1 (de) * 2005-01-10 2011-10-12 Cortendo AB (publ) 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
JP2006206605A (ja) * 2006-03-29 2006-08-10 Metabolic Syndrome I Goeteborg Ab 代謝性症候群の治療薬
EP1886695A1 (de) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmazeutische Kombinationen mit einem Aldosteron Synthasehemmer und Glucocorticoid Rezeptorantagonisten oder Cortisol Synthasehemmer oder Corticotropin Releasing Faktor Antagonisten
RU2009116632A (ru) 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) Энантиомер кетоконазола у людей
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
SI0779810T1 (en) * 1994-08-09 2003-12-31 Cortendo Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure

Also Published As

Publication number Publication date
DE69432905D1 (de) 2003-08-07
DE69432905T2 (de) 2004-05-27
WO1996004912A1 (en) 1996-02-22
NO970567L (no) 1997-02-07
EP0779810A1 (de) 1997-06-25
CA2196174A1 (en) 1996-02-22
NO970567D0 (no) 1997-02-07
KR970704440A (ko) 1997-09-06
EP0779810B8 (de) 2003-09-17
EP1360960A1 (de) 2003-11-12
EP0779810B1 (de) 2003-07-02
KR100422162B1 (ko) 2004-07-07
NO314616B1 (no) 2003-04-22
AU695011B2 (en) 1998-08-06
AU7711894A (en) 1996-03-07
PT779810E (pt) 2003-11-28
CZ36097A3 (en) 1997-06-11
CZ285290B6 (cs) 1999-06-16
JP3825469B2 (ja) 2006-09-27
SI0779810T1 (en) 2003-12-31
CA2196174C (en) 2005-03-01
JPH10510241A (ja) 1998-10-06
US6166017A (en) 2000-12-26
US5849740A (en) 1998-12-15
ATE244009T1 (de) 2003-07-15
ES2202326T3 (es) 2004-04-01

Similar Documents

Publication Publication Date Title
DK0779810T3 (da) Anvendelse af ketoconazol og beslægtede stoffer i medikamenter til behandling af type II-diabetes
IS5194A (is) Notkun þíasólídíndíonafleiða við meðferð á fjölblöðrueggjastokkaheilkennum og þungunarsykursýki
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
KR970706002A (ko) 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men)
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
ATE367169T1 (de) Verwendung von exendins und deren agonisten zur behandlung von schwangerschaftsdiabetes
DE60042598D1 (de) Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.
NO20006194D0 (no) Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
NO20041203L (no) Human glukagonlignende peptid-1 etterligner og deres anvendelse i behandling av diabetes og relaterte tilstander.
DK0616812T3 (da) Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer
NO974824D0 (no) Arteriovenöse og venös transplantasjonsbehandlinger, fremgangsmåter og blandinger
IS5756A (is) Notkun hreinljósvirks (+) -norkisapríðs við meðhöndlun á öndunarstöðvun, lotugræðgi og öðrum meinum
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
PT1214061E (pt) Nova utilizacao de docetaxel para o tratamento do carcinoma hepatocelular
JP2003528919A5 (de)
EP1757302A8 (de) Adiponectin-expressionsinduktor und seine verwendung
NO894008D0 (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
WO2005053728A3 (de) Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
DK1865990T3 (da) Fremgangsmåde til behandling af type 2 diabetes
DE69909636D1 (de) Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor
EP1073471A4 (de) Verfahren zur behandlung von endotoxemia
鍾宏銘 et al. Becker's Melanosis: Associated with Ipsilateral Lower Limb Hyperplasia and Pectus Excavatum-A Case Report and Review of the Literature
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)